Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide ...

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza ...

Bengaluru: Biocon Limited, an innovation-led global biopharmaceutical company, has announced the launch of its GLP-1 peptide, ...

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

Biocon launches Liraglutide, a GLP-1 peptide, in the UK for diabetes and obesity management. This marks the first generic ...

Shares of Biocon Ltd took a hit on Friday, February 28, 2025, slipping to a day’s low of Rs 300.10, marking a 3.92 per cent ...

Biocon has announced the launch of its GLP-1 peptide Liraglutide for diabetes and obesity in the United Kingdom (U.K.).

Liraglutide in United Kingdom: Our Bureau, Bengaluru Friday, February 28, 2025, 15:30 Hrs [IST] Biocon Limited, an innovation-led global ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

NTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore ...